Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10101088 | Urology Case Reports | 2018 | 4 Pages |
Abstract
Cisplatin-based systemic chemotherapy is the gold standard for the treatment of patients with metastatic urothelial carcinoma (UC), which is a chemosensitive cancer. However, long-term survival has been deemed disappointing. We describe here a case of UC with solitary pulmonary metastasis who had successfully achieved long-term disease-free survival by combination of cisplatin-based chemotherapy and pulmonary metastasectomy. From the finding of this article, we propose that adjuvant chemotherapy may be considered as a viable option after metastasectomy in low volume pulmonary metastatic UC patients.
Related Topics
Health Sciences
Medicine and Dentistry
Urology
Authors
Kenichi Hasebe, Taku Naiki, Risa Oda, Toshiki Etani, Keitaro Iida, Yosuke Sugiyama, Satoshi Nozaki, Ryosuke Ando, Noriyasu Kawai, Ryoichi Nakanishi, Takahiro Yasui,